Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Recently, the signing and unveiling ceremony of Medtronic's Digital Healthcare Innovation Base was held at the International Pharmaceutical Innovation Park (BioPark) located in Yizhuang New City, Beijing.

According to reports,This base is the first digital healthcare innovation base established by Medtronic in China.

According to reports, the Medtronic Digital Health Innovation Base is dedicated to developing disease management solutions based on artificial intelligence and big data.Will focus on building medical training centers in the fields of cardiovascular, minimally invasive surgery, and neuroscience; establish a patient care center, introduce digital technology to enhance the level of preventive management services for patients; and build the Medtronic Museum.The innovation base will be officially put into operation by the end of this year.

△ The first digital healthcare innovation hub established by Medtronic in China.

The base is located in the International Medical Innovation Park (BioPark) in the western part of Yizhuang New Town, Beijing. It is adjacent to the southern central axis on the west, with the southern fifth ring road and JingTai Expressway as well as Metro Line 8 running through the area. Covering an area of 5.8 square kilometers, it is an important industrial functional zone in the comprehensive supporting service area of Yizhuang New Town and even the southern part of the capital.

This location not only hosts all six major centers of the National Medical Products Administration, but also attracts several multinational companies, including Medtronic.Including Eli Lilly, Pfizer, Bayer, Huya Bio, and AstraZeneca.Most of the newly established R&D or innovation institutions by these companies are "the first in Beijing" or "the first in China." For instance, Bayer will establish an Open Innovation Center; Eli Lilly will set up the China Medical Innovation Center in Yizhuang, Beijing; Pfizer will establish its first physical R&D center in Beijing; and HUYA Bioscience will set up its China headquarters, becoming the first international platform in Beijing dedicated to the overseas promotion of innovative drugs. According to the plan, this year, investments in the International Pharmaceutical Innovation Park will reach 10 billion yuan.

△International Medical Innovation Park BioPark.

BioPark will be planned and built as a global hub for pharmaceutical and health innovation cooperation, an international influential biopharmaceutical industry innovation cluster, the first stop for global pharmaceutical innovation talents to start businesses in China, a demonstration zone for AI empowerment applications in China's pharmaceutical and health industry, and a "test field" for the implementation of national innovative pharmaceutical policies.

"After 36 years of deep cultivation in China, Medtronic has always been driven by innovation, resonating with the development of China's healthcare industry. The establishment of the Digital Healthcare Innovation Hub in Beijing marks a new phase in our full value chain presence in China. We hope to leverage Beijing’s leading medical resources and innovative momentum to collaborate with partners in creating a patient-centric digital healthcare innovation model.Reduce hospital burden, improve service efficiency, and enhance patient chronic disease management experience with solutions such as remote management and intelligent follow-up.", helping China build a smart and inclusive healthcare system." said Jeff Marx, Global Chairman and Chief Executive Officer of Medtronic.

Notably, the senior management of Medtronic has recently participated in several significant events and leadership meetings in China.

He Licheng Meets with Heads of Multinational Corporations

On March 23, He Lifeng, Member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, met with the heads of well-known multinational companies such as Medtronic, Apple, Pfizer, and Eli Lilly and Company to exchange views on the global and Chinese economic situation, China-U.S. economic and trade cooperation, and expanding investment in China.

He Lifeng stated that China's economy is resilient, with great potential and vitality. China is firmly committed to promoting high-quality development, expanding high-level opening-up, and continuously optimizing the business environment.Welcome multinational companies to expand investment in China and share development opportunities.

The head of the multinational company expressed重视 (importance) for the Chinese market, optimistic about China's economic prospects, and is willing to commit to long-term cooperation with China.

China Development Forum 2025 Annual Meeting

From March 23 to 24, the 2025 Annual Meeting of the China Development Forum was held in Beijing with the theme "Fully Unleashing Development Momentum, Jointly Promoting Stable Global Economic Growth," attracting political leaders from multiple countries and numerous heads of multinational corporations to attend the meeting in China.

Medtronic Chairman and CEO Jeff Martha said during the annual meeting,Medtronic believes that China will become the world's largest medical market and an important source of innovation, as well as a strategic hub for medical innovation, investment, and cooperation.Medtronic looks forward to collaborating with more industry partners to jointly promote the development of new quality productivity, advance healthcare innovation, and improve patient outcomes.

Jeff Massa said: "In 2025, Medtronic will enter its 36th year of development in China. Considering China's demographic structure, growing healthcare needs, and the broader trend of China's economic development, the potential of China's healthcare market is undoubtedly enormous."

Visit Chengdu

On March 25, Cao Lijun, Member of the Standing Committee of the Sichuan Provincial Party Committee and Secretary of the Chengdu Municipal Party Committee, met with Jeff Marshall, Chairman and Chief Executive Officer of Medtronic Global, and his entourage.

Cao Lijun welcomed Jeff Masa and his delegation's visit to Chengdu for exchanges and cooperation promotion, briefly introducing the economic and social development of Chengdu. He said that Chengdu is a hub city for Chinese and foreign exchanges and one of the most dynamic and happiest cities in China. It is currently building a park city demonstration zone that practices new development concepts in an all-round way, aiming to create a socialist modern international metropolis with global influence and reputation. As a world-leading medical technology enterprise, Medtronic has maintained a good cooperative relationship with Chengdu for a long time. We hope that the company will continue to increase its investment layout in Chengdu, bring more high-quality products, technologies, and services to China and implement them in Chengdu, strengthen exchanges and cooperation with Chengdu, and achieve win-win development. We will adhere to the principle of "responding to all needs and not disturbing when there is no need," regularly carry out the work of "entering ten thousand enterprises, solving problems, optimizing the environment, and promoting development," continuously create a first-class business environment that is market-oriented, law-based, and internationalized, and fully create favorable conditions and provide quality services for the development of enterprises.

Jeff Massa said that Chengdu has the advantages of industry, talent, technology, and market, with vibrant economic development, and he has high hopes for Chengdu's future.Will increase investment and cooperation in Chengdu, expand the layout of the industrial chain and value chain, actively integrate into the local innovation ecosystem, and promote the落地application of new products and technologies in Chengdu., to boost the high-quality development of Chengdu's pharmaceuticals and health industry, and make greater contributions to enhancing citizens' health and well-being.

In recent years, Medtronic has continued to increase its investment in China, building a localized full value chain layout. The key focus of the layout:

Lingang Medical Technology Industry Base is a cardiac disease management base that integrates high-end medical technology research and development with localized production, dedicated to providing China-tailored solutions for cardiac disease management. The base's first product rolled off the production line last year.

Kanghui Changzhou Science and Technology Park is a comprehensive innovation park in the orthopedics and neurosurgery fields, integrating production, research and development, incubation, and customer experience. The completion of this science park will have a profound impact on the medical technology industry in the Yangtze River Delta region. Currently, the building has been topped off, and the new building of the science park is expected to be put into use in 2026.

Changzhou Kangdi Production Base: The Medtronic Kangdi Integrated Surgical Base project plans to introduce the most cutting-edge products and technologies in the global surgical field, creating a "smart" manufacturing base and innovation center that combines the production of high-end surgical products and equipment with innovative R&D incubation. This is an important layout by Medtronic in the surgical field. The project was officially signed on October 18 last year.

The Beijing Yizhuang Digital Innovation Service Base, which hosted this signing and unveiling event, represents an important endeavor by Medtronic in the field of digital healthcare. It is evident that Medtronic's layout in China is expanding across various fields and regions.

On February 18, 2025, Medtronic announced its financial results for the third quarter (Q3) of fiscal year 2025.The report shows that the company's revenue reached approximately US$8.3 billion (approximately RMB 61.093 billion), growing by 2.5% on a reported basis and 4.1% on an organic basis.Achieved mid-single-digit organic revenue growth for the ninth consecutive quarter. Going forward, with continued investment, can China further enhance its boost to Medtronic's performance? Medical Device News will continue to monitor the situation.